Marcin Dzienis Clinical Oncology Society of Australia Annual Scientific Meeting 2026

Abstracts this author is presenting:

• Overcoming tumor penetration barriers via dual EGFR/TGF-β inhibition: A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo with pembrolizumab in first-line recurrent or metastatic (R/M) PD-L1-positive, HPV-negative head and neck squamous cell carcinoma (HNSCC): The FORTIFI-HN01 study — Wednesday Poster Session